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Abstract
Background: Non-alcoholic fatty liver disease, the most prevalent liver disease in developed countries, remains
difficult to manage with no proven safe and effective pharmacotherapy available. While weight reduction is the
most commonly practiced treatment strategy, this is difficult to both achieve and/or maintain in the majority.
Furthermore evidence-based dietary recommendations to guide the nutritional management of these patients are
lacking. Using a randomised controlled trial design, this study compares the effectiveness of the Mediterranean diet
to a standard low fat diet in terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in
participants with non-alcoholic fatty liver disease.
Methods: Ninety four eligible patients who have non-alcoholic fatty liver disease and who are insulin resistant, will
be randomised into either a Mediterranean or low fat diet group for a 3 month intervention period. Insulin sensitivity
will be measured on peripheral blood using Homeostatic Model Assessment and liver fat content quantified using
Magnetic Resonance Spectroscopy. Both arms will consist of three face to face and three telephone call follow up
consultations delivered by an Accredited Practicing Dietitian. The intervention arm focuses on recommendations from
the traditional Mediterranean diet which have been tailored for use in the Australian population The standard arm uses
the Australian Guide to Healthy Eating and the Australian National Heart Foundation dietary guidelines. Study recruitment
will take place at four major metropolitan hospitals in Melbourne, Australia. Data collection will occur at all face to face
reviews including baseline, 6, and 12 weeks. A follow up assessment to measure sustainability will take place at 6 and
12 months. The primary end point is improved insulin sensitivity scores at the 12 week time point.
Discussion: This trial aims to demonstrate in a large cohort of participants with NALFD that a Mediterranean diet
independent of weight loss can result in significant benefits in liver fat and insulin sensitivity and that these changes are
sustained at 12 months. These metabolic changes would potentially lead to reductions in the risk of chronic liver disease,
heart disease, type 2 diabetes and liver cancer.
Trial registration: Australia and New Zealand Clinical Trials Register ACTRN: ACTRN12615001010583.
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Background
Non-alcoholic fatty liver disease (NAFLD) and its pro-
gressive form, non-alcoholic steatohepatitis (NASH) are
among the most prevalent of liver diseases worldwide.
Approximately 20 to 30 % of the adult population has
NAFLD, making it the most common liver disease in
developed countries [1–3]. The incidence is as high as
50–85 % in people with pre-diabetes and diabetes [4, 5],
with diabetic patients having a two to threefold higher
risk of dying of chronic liver disease, primarily attribut-
able to NAFLD [6]. In addition, NAFLD has been associ-
ated with the occurrence of cardiovascular disease
(CVD), independent of the classical risk factors [7].
CVD is the leading cause of death in Australia and glo-
bally [8]. An estimated 30 % of patients with NAFLD
have NASH, which leads to cirrhosis and its complica-
tions including, portal hypertensive bleeding, hepatocel-
lular carcinoma and hepatic decompensation [9]. Insulin
resistance is strongly implicated in the development of
steatosis (fatty liver) and its progression to NASH. The
clinically relevant lesion progresses to cirrhosis in
20–30 % of cases and leads to liver cancer in 2–5 % of
cases [10]. Currently no proven, safe, effective therapy
exists for NAFLD and NASH [11]. Given the increasing
prevalence of these conditions and high incidence of as-
sociated metabolic comorbidities, the global burden is
expected to steadily increase.
Diet is a modifiable risk factor that can potentially be tar-
geted in both the prevention and treatment of NAFLD.
Currently no firm dietary recommendations can be formu-
lated in the management of NAFLD because of the paucity
of high quality evidence-based data associated with
metabolic outcomes. However current data suggests that
patients should aim to achieve a 5–10 % weight reduction,
reduce saturated and trans fat, limit fructose, limit intake of
simple carbohydrates and substitute with complex carbohy-
drates such as whole grains, fibre and fruits [12–14].
However, weight loss is neither easy to achieve or maintain
and weight loss achieved in research trials is not easily rep-
licated in the clinic or real world settings. As such, there is
an urgent need for therapies independent of weight loss.
The health benefits of the Mediterranean Diet (MedDiet)
have gained popularity in the scientific literature and lay
world with respect to being one of the healthiest diets in
the world. Its effects are well researched in high quality
studies such as PREDIMED and benefits are attributed to a
lower incidence of chronic disease including CVD, obesity,
dementia, some cancers, and overall mortality demonstrat-
ing its safety, palatability and sustainability [15].
Pilot data to support the shift from current dietary
therapy to a novel MedDiet intervention of patients with
NAFLD has been published by Ryan et al. in NAFLD
patients [16]. This study demonstrated a significant
improvement in insulin sensitivity and hepatic steatosis
with the MedDiet compared to no change in the low fat
diet group.
This study, MEDINA (Mediterranean Dietary Inter-
vention study in Non-alcoholic fatty liver disease) aims
to replicate the findings of Ryan et al’s pilot study ina
larger cohort of participants with NAFLD in a more
translatable environment and with assessment of sus-
tainability. The study aims to investigate the effects of
adhering to the MedDiet as compared to a low fat diet.
We hypothesise that the MedDiet will demonstrate a po-
tential to reverse insulin resistance and reduce fatty liver
and that the benefits will be sustained 12 months post
study initiation date with maintenance of the diet. We
also aim to explore molecular mechanisms at play in the
disease process and the interplay with diet.
Methods
Study design and outcome measures
This is a 12 week, multi-centre, parallel, randomised
controlled trial of a Mediterranean diet versus a Low Fat
Diet (LFD) in patients with NAFLD on insulin resistance,
hepatic steatosis and Metabolic Syndrome (MetS) risk fac-
tors. Enrolment of 94 participants will occur at four sites
across metropolitan Melbourne, Australia: Alfred Health,
St Vincent’s Hospital, The Royal Melbourne Hospital and
Eastern Health. Both the recruitment and intervention are
anticipated to take place over a 24 month period. Partici-
pants will undergo stratified randomisation according to
gender and diabetes status, into either the intervention;
MedDiet or the LFD arm. The primary endpoint is the re-
duction of one unit of homeostasis model assessment of
insulin resistance (HOMA-IR) over the 12 week inter-
vention period. Secondary outcome variables include a
reduction in intrahepatic lipid accumulation measured
by Magnetic Resonance –Spectroscopy (MR-S), norma-
lisation or improvement of alanine aminotransferase
(ALT), lipid profile, liver stiffness as measured by tran-
sient elastography (Fibroscan®), inflammatory cytokine
markers, quality of life measures, anthropometry and
body composition, biomarkers of dietary intake and
blood pressure.
Participant recruitment and eligibility
Participants will be recruited from the outpatient Liver
Clinics of four major metropolitan University hospitals
via referral from the managing hepatologist of poten-
tially eligible participants for screening. Screening will be
performed by a trained researcher.
Inclusion criteria
Participant eligibility includes those aged >18 years who
have a body mass index (BMI) between 20 and 39.9 kg/m2.
Participants must have a diagnosis of NAFLD determined
by routine ultrasound or biopsy; insulin resistance based
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on a HOMA IR score of >2; and at least one elevated
serum ALT level (>20 U/L female, >30 U/L male) during
the past 6 months. Eligible participants must have no evi-
dence of another form of liver disease.
Exclusion criteria
Participants will be excluded if they:
 Refuse or are unable to give informed consent to
participate in the study;
 Are Non-English speaking;
 Consume on average >140 g/week of alcohol
(men and women);
 Are taking the following medications:
immunosuppressants, amiodarone and/or
perhexiline;
 Have had a weight change exceeding 5 kg within
3 months;
 Are currently following or anticipated to commence
a specialised commercially available weight loss diet
and/or program (eg. Light and Easy, Optifast etc.);
 Have a diagnosis of insulin dependent diabetes
mellitus or those taking gliclazides;
 Have a HbA1c score exceeding 8 %;
 Have a current or prior history of cardiovascular,
cerebrovascular or peripheral vascular disease;
 Have clinically relevant pulmonary, gastro-intestinal,
renal, metabolic, hematological, neurological,
psychiatric, systemic or any acute infectious
disease or signs of acute illness;
 Are women who are pregnant;
 Have psychosocial or gastrointestinal
(e.g. malabsorptive conditions e.g. coeliac)
 Have contraindications included bulimia nervosa,
substance abuse, clinically significant depression,
or current psychiatric care;
 Have had a recent (within 3 months) of change
in dose/regime or introduction of vitamin E, C
or high dose vitamin D (>3000 IU), fish oil or
probiotics.
Timeline of assessments
All participants will complete a face-to face dietary and
lifestyle assessment and consultation, anthropometry
and biochemistry at baseline, mid-intervention (6 weeks)
and end-intervention (12 weeks). Participants from both
groups will also undergo phone call follow up reviews at
weeks 2, 4 and 9. All participants will undergo assessment
of hepatic steatosis with MR-S and fibrosis with Transient
Elastography; Fibroscan® at baseline and end-intervention.
Dual-energy X-ray absorptiometry (DXA) scans are volun-
tary and will assess body composition. All participants will
be followed up face to face at 6 and 12 months after study
recruitment to determine maintenance and sustainability
of the diet administered and subsequent changes in im-
aging and biomarkers. Please refer to Table 1 for the
schedule of measures.
Study procedure
Screening assessment
Prospective participants will undergo a thorough screen-
ing questionnaire administered face-to-face by a trained
researcher. Once considered eligible, participants will
undergo computer generated randomisation stratified to
gender and diabetes status completed by the statistician.
Participants will be allocated into either the LFD or the
MedDiet arm of the study and booked in for their initial
appointment.
Randomisation will control for equal distribution of key
characteristics that may confound between group compari-
sons and will be assessed by analysis of baseline data.
Dietary interventions
Mediterranean diet
The intervention is based on a traditional MedDiet as
described in Keys et al. in the seven countries study and
the macro and micronutrient compositions described in
previous MedDiet controlled trials [17–20]. The diet is
rich in plant based foods including vegetables, whole
grains and fruit with the main added fat being extra vir-
gin olive oil. The diet emphasises increased legumes and
raw unsalted nut intake and oily fish. Moderate amounts
of fermented dairy and poultry with small amounts of
red meat and homemade sweets. The diet comprises of
44 % fat (>50 % monounsaturated), 36 % carbohydrate
and 17–20 % protein and up to 5 % alcohol. The diet
was designed to be easy to follow and sustainable with
an ad libitum approach focusing on what should be con-
sumed rather than what to avoid. All changes to diet
and lifestyle will be administered to participants by an
Accredited Practising Dietitian (APD) who is able to tailor
the diet to cultural and personal preferences through
recommendation of nutritionally appropriate alternatives
where necessary.
All participants will be provided with written resources
specifically designed to explain the MedDiet and how it can
be successfully followed and adhered to. These resources
include a food pyramid, healthy eating guidelines and tips,
meal plans, recipes in the form of; The Mediterranean Diet
recipe book by Itsiopoulos (ISBN 9781742610825), a shop-
ping list, ‘no cooking’ meal options and label reading. Par-
ticipants will also be asked to set individual goals at each
session which will be used as a focal point for subsequent
phone call follow ups and appointments and will assist with
having directed changes and maintaining motivation.
Participants will also be supplied with extra virgin olive
oil (Cobram Estate©) for the duration of the interven-
tion and some MedDiet specific food items such as
Papamiltiadous et al. BMC Gastroenterology  (2016) 16:14 Page 3 of 7
nuts (Almond Board Australia), canned legumes and
fish (Simplot Australian Pty Ltd and HJ Heinz©) which
are aimed at providing practical and convenient examples
of what items constitute a MedDiet. Breakfast is also pro-
vided on the day of all face to face appointments (Jalna ©
and Carmen’s ©).
Low fat diet
The LFD group will follow the same structure as the
MedDiet arm with three face to face consultations at
baseline, 6 weeks (mid intervention) and 12 weeks (end
of intervention). There will also be the same number of
phone call follow ups at weeks 2, 4 and 9. The education
and resources provided will be determined by the APD
running the consultations and these will involve what
would normally be provided in a typical outpatient dietetic
consult. This will include based on the Australian Guide
to Healthy Eating with an emphasis on portions, low fat
options and cooking methods. Participants will also be
given a supermarket gift voucher to purchase some of the
suggested food items.
Breakfast is also provided on the day of all face to face
appointments (Jalna © and Carmen’s ©).
Outcome measures
The outcome measures collected and their parallel time-
lines are displayed in Table 1. Patient information in-
cluding demographic data, smoking status, medication
and supplement consumption are taken at baseline and
checked at each face-to-face appointment for changes.
Anthropometry
Weight, height, waist circumference, hip circumference,
neck girth and blood pressure will be taken using standard
procedures, in duplicates by a trained researcher at all face
to face appointments.
Body Composition will be assessed using Seca© bio
electrical impedance analysis scales at all face to face ap-
pointments. DXA scans using a Hologic© machine will a
be used to assess body composition in a consenting volun-
teer subset of participants.
Dietary and lifestyle
Three day food diaries including 2 weekdays and 1
weekend, a Food Frequency Questionnaire (FFQ) and
the PREDIMED Checklist (a measure of dietary compli-
ance specifically designed to measure key elements of the
diet administered for each study arm) will be collected
Table 1 Schedule of measures
Variable Instrument Time point
Self-reported Baseline Mid intervention End intervention 6 month 12 month
Diet intake Food Frequency Questionnaire
(FFQ), 3- day food diary
X X X X X
Diet compliance PREDIMED checklist (low fat or MD) X X X X X
Physical activity Active Australia Questionnaire X X X X X
Quality of life SF-36 X X X X X
Medications and supplements Self-report X X X X X
Smoking status Self-report X
Ethnicity Self-report X
Medical history Self-report and clinical records X X X X X
Anthropometric and clinical
Weight, height, waist and hip
circumference, neck girth
X X X X X
Blood pressure X X X X X
Whole body composition Bioelectrical Impedance Analysis
(BIA), DXA (subgroup)
X X (NO DXA) X X (NO DXA) X
Intrahepatic lipids MR-S X X X
Liver fibrosis Fibroscan X X X
Pathology
Venous blood sample (fasting) X X X X X
First morning urine sample X X X X X
Buccal swab X
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from participants at baseline, mid intervention and post
intervention to assess dietary compliance relative to the
recommendations provided. The Active Australia ques-
tionnaire will monitor changes in physical activity. The
Short Form Health Survey (SF- 36) will be used to col-
lect quality of life data. All questionnaires will also be
administered at 6 and 12 months to observe any sus-
tained behaviours and thus the ability to maintain the
recommended changes and any metabolic benefits.
Imaging
MR-S images will be taken by a qualified radiographer
using a Simmens© MRI machine and will be used as the
gold standard to monitor changes in the percentage of
intrahepatic lipids in the liver. Following a minimum 2 h
fast, Transient Elastography (FibroScan®) will be taken in
patients to monitor changes to liver fibrosis throughout
the study duration.
Laboratory
Pathology blood samples will be prepared by the nomi-
nated laboratories or researchers according to standard
protocol. Once prepared samples will be processed and
plasma will be stored in −80 °C freezers at the Department
of Gastroenterology, The Alfred Hospital Prahran and the
Department of Dietetics and Human Nutrition, La Trobe
University Bundoora campus until batch analysis of assays
are performed.
Plasma fatty acids and urinary metabolites both represent
key markers of dietary compliance and will be processed
and analysed at La Trobe University. Peripheral blood
mononuclear cells (PBMCs) will be utilised to assess meta-
bolomics investigating the genetic variations in genotype/
phenotype and will be processed and analysed using poly-
merase chain reaction (PCR) at La Trobe University. A
buccal swab will also be taken at baseline for all partici-
pants to assess the DNA profile of the study population.
Data management
The key researcher at each site will be responsible for
storage of hard copies of coded case report forms and
questionnaires which will be in kept in secure filing cabi-
nets. All electronic data will be saved in a password pro-
tected database. Participants who are interested in the
study results will be flagged and individual and overall
data will be disseminated at the conclusion of the study.
Study integrity
Approval to carry out the study was obtained from La
Trobe University, the Alfred, Eastern Health, Royal
Melbourne Hospital’s research and ethics committee
and ethics review is currently underway at St Vincent’s.
Written informed consent will be obtained from all par-
ticipants. This randomised control trial protocol has
been designed with close consideration of the CON-
SORT guidelines [21]. In addition this study protocol
has been reviewed by the La Trobe University Research
Focus Area board who provided seed funding for the
commencement of this trial.
Sample size
We aim to recruit 47 participants per arm (94 in total)
allowing for a 20 % drop out rate over 12 months. This
sample size has been calculated with 80 % power to detect
a between-group difference in HOMA-IR of 1.0 unit or
more at the end of the 12 week duration, with the as-
sumed standard deviations for control and intervention
groups of 0.118 and 0.141, respectively. The assumed
mean difference and group-specific standard deviations
were calculated based on the following past studies: Ryan
[16], Esposito [22], Esposito [23] and Elhayany [24].
Statistical analysis
Intention-to-treat (ITT) principle will be used to analyse
and compare the intervention and control groups. As
per ITT principle, for the purpose of statistical analyses,
all participants will retain their randomised (allocated)
group, regardless of the actual treatment received. T-test
will be used to examine the effectiveness of randomisa-
tion by comparing baseline characteristics across the
two groups. If data are not normally-distributed, non-
parametric Kruskal-Wallis test will be used instead.
For quantitative endpoints (e.g., HOMA-IR), linear
mixed-effect models will be used to compare the inter-
vention and control group. If normality assumption is
not fulfilled, suitable transformation (e.g., log) will be
performed on the response variable to ensure the assump-
tion is met. For binary endpoints (e.g., improvement in
lipid profile >20 %), mixed-effect logistic regression for
longitudinal data will be used. In both cases, data from all
participants, including those who withdraw after baseline,
will be retained for analyses. When required, potential
confounders (e.g., age, BMI) will be adjusted for by in-
cluding them as additional covariates in the models.
When multiple hypothesis testings are performed (e.g.
with SNP data), Holm’s procedure (Holm, 1979) will be
used to control the familywise error rate. All statistical
analyses will be performed using 5 % significance levels.
R version 3.1.1 (www.r-project.org) and STATA version
12 will be used to conduct the statistical analyses.
Discussion
Currently, there are no safe or effective proven therapies
for the treatment of patients with NAFLD or NASH [25].
While diet and lifestyle changes focussing on achieving
weight loss are the accepted recommendations for this pa-
tient group, weight loss is both difficult to achieve and
maintain [26–28]. Despite this there have been a limited
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number of randomised controlled trials in this patient
group and no specific diet has been identified as superior to
another [29, 30]. In a cross-over study [16] which forms the
pilot data for this trial, patients in the MedDiet arm had sig-
nificant improvements in insulin sensitivity as determined
by a 3-hour hyperinsulinaemic-euglycaemic clamp and a
significant reduction (39 %) in hepatic steatosis. In con-
trast there was no significant improvement in insulin
sensitivity and only a 7 % reduction of hepatic steatosis
with the low fat, high carbohydrate diet. The changes
observed in the intervention group were without a sig-
nificant reduction in weight [16]. The MedDiet has
positive effects on insulin sensitivity, which has been at-
tributed to the high content of bio-active phytochemi-
cals with a range of antioxidant and anti-inflammatory
activity [31]. The MedDiet is characterised by a specific
fatty acid profile: low in saturated fat (7–8 % of total
energy) and high in monounsaturated fat (20 % of total
energy). A Spanish study showed that treatment with a
balanced diet rich in olive oil contributes to the recov-
ery of the liver from hepatic steatosis [32]. This was
achieved by decreasing activation of hepatic stellate cell
(decrease hepatic collagen) by monounsaturated fatty
acids, which is less susceptible to lipid peroxidation as
compared to polyunsaturated fatty acids.
This study aims to assess the MedDiet in NAFLD pa-
tients to determine whether this dietary pattern is superior
compared to the current recommendations for patients,
thus developing a more evidence based therapy that can be
translated into the clinical setting. In addition by addressing
diet and lifestyle factors there is likely to be secondary pre-
vention of associated chronic diseases such as type 2 dia-
betes and CVD which are shown to share some
pathophysiological similarities with NAFLD.
This study is also one of the first randomised controlled
trials assessing the MedDiet in a non-Mediterranean
country. Thus, will provide insight into implementation of
the dietary principals across various cultures and the feasi-
bility and sustainability of these changes in specific ethnic
groups. The novel markers of compliance including food
diaries and food frequency questionnaires will also be sup-
ported by robust markers such as plasma fatty acids and
urinary metabolites. Other lifestyle changes including
physical activity will be measured using the Active
Australia Questionnaire and will be considered in the as-
sessment of final results.
Although environmental influences such as diet have a
well-established association with disease it is important to
acknowledge that the interplay of genetics and environment
are a widely accepted influence in disease outcomes. The
relationship between the genome and nutrition (nutrige-
nomics) is a growing area of research. Studying nutrition
alongside genetics is vital as it is now well established that
even small differences in gene sequences can alter the
metabolic pathways which make individuals more or less
responsive to certain diets [33]. Investigating the genotype
in terms of response and non-response to the MedDiet in
an exploratory manner enhances the understanding at the
genomic and molecular level. By examining the associated
phenotype with anthropometric and biochemical indices in
a NAFLD population and correlating these to inflammation
and markers of insulin resistance may help to identify indi-
viduals at greater cardio metabolic risk.
This intervention study has the capacity to provide a
cost effective and sustainable therapy for large and in-
creasing patient group which we feel would be highly
acceptable and widely applicable at a community level,
with the potential to reduce cost burden on society and
improve health outcomes for individuals.
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